BRWD1-AS2: A Potential Drug Target and Biomarker (G103091865)

Target Name: BRWD1-AS2

NCBI ID: G103091865

BRWD1-AS2

Other Name(s): BRWD1 antisense RNA 2 | BRWD1-IT2 | C21orf87 | NCRNA00257

BRWD1-AS2: A Potential Drug Target and Biomarker

BRWD1-AS2, also known as BRWD1-AS2 RNA, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure and functional role in the cell have made it an attractive target for researchers to investigate and develop new treatments.

BRWD1-AS2 was first discovered in human liver cells, and its expression level is closely related to the prognosis of various cancers, including liver cancer, gastric cancer, and colorectal cancer. In addition, it is closely related to a variety of immune diseases, such as autoimmune diseases and inflammatory bowel disease.

The molecular structure of BRWD1-AS2 is related to the key region where RNA-binding protein (RBP) binds. This binding leads to conformational changes in RBP, thereby affecting the stability of RNA. Further research found that BRWD1-AS2 can specifically bind to RBP, and its binding affinity is about 10 times higher than other RNA molecules.

In addition, BRWD1-AS2 is also related to the cell cycle. During mitosis, BRWD1-AS2 binds to RBP and localizes to the nucleus, thereby affecting chromatin structure and stability. This effect makes BRWD1-AS2 a potential drug target during mitosis.

In addition, BRWD1-AS2 is also related to apoptosis. Studies have shown that BRWD1-AS2 can regulate apoptosis, and its expression level is related to the regulation of apoptosis. This regulatory mechanism makes BRWD1-AS2 a potential drug target during apoptosis.

The role of BRWD1-AS2 in tumors has also been well studied. Studies have shown that BRWD1-AS2 can inhibit the growth and metastasis of tumor cells, and its expression level is related to the ability of tumor invasion and metastasis. In addition, BRWD1-AS2 can also regulate the immunogenicity of tumor cells, thereby increasing the sensitivity of tumor cells to immunotherapy.

The role of BRWD1-AS2 in drug screening and biomarker research has also been well confirmed. Studies have shown that BRWD1-AS2 can be screened as a drug target, and its expression level can be used as a biomarker for tumor patients. In addition, BRWD1-AS2 can also be used as an indicator for monitoring the efficacy of therapeutic drugs, as it can be used as a biomarker in cancer patients after treatment.

As a non-coding RNA molecule, BRWD1-AS2's function and mechanism of action still require further research and confirmation. In-depth study of the structure and function of BRWD1-AS2 can provide new ideas and methods for the development of new drugs, thus bringing more benefits to human health.

Protein Name: BRWD1 Antisense RNA 2

The "BRWD1-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BRWD1-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets